BioClinica Launches WebSend and Creates Efficiencies for Clinical Trial Imaging Delivery

BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced the release of BioClinica WebSend, a system that simplifies and accelerates image collection for clinical studies. WebSend transfers and tracks medical images in real-time, offering key benefits over the standard manual transport methods commonly used in imaging trials, including faster delivery of image data, enhanced data quality with fewer site queries, and reduced cost.

BioClinica WebSend is complemented by BioClinica WebView, the proven and established solution for managing the electronic sharing, blinding, tracking, archiving and analysis of medical images for clinical trials worldwide. Originally developed over 10 years ago by CardioNow, a business acquired by BioClinica from Agfa HealthCare in August 2009, BioClinica WebSend and WebView have evolved into a best-in-class solution for delivering true electronic clinical trial image management.

"BioClinica WebSend offers clients speed and flexibility that is simply not available with other image transport solutions. It allows any investigator site or imaging center globally to send all medical images to BioClinica electronically in a secure, regulatory-compliant manner. Along with BioClinica WebView, WebSend manages the collection and validation of those images,” said Mark L. Weinstein, CEO of BioClinica, Inc.

"BioClinica WebSend and BioClinica WebView are further examples of how BioClinica continues to develop innovative solutions to help our customers better manage their clinical studies and achieve the best possible results. We remain committed to driving the advancement of image management for clinical trials with a blend of new technologies and services,” said David Pitler, President of BioClinica’s Bioimaging Services Division. "The launch of these enhanced products exemplifies that commitment.”

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management, and clinical supply chain forecasting and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.